Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions

Author(s): Alexander Joost, Volkhard Kurowski and Peter W. Radke

Volume 14, Issue 12, 2008

Page: [1176 - 1185] Pages: 10

DOI: 10.2174/138161208784246126

Price: $65

Abstract

The administration of heparins (unfractionated or fractionated) represents the current standard as anticoagulant treatment during percutaneous coronary intervention in different clinical settings (elective cases and acute coronary syndrome). Since the incidence of heparin-induced thrombocytopenia (HIT) is expected to range between 0.1 and 5%, the application of an appropriate anticoagulant agent has become a mandatory issue. This review will provide current pathophysiological insights of HIT as well as contemporary alternative anticoagulant strategies during PCI in patients with or at risk of HIT.

Keywords: Heparin-induced-thrombocytopenia, HIT, PCI, argatroban, bivalirudin, lepirudin, danaparoid, fondaparinux


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy